MERTK and neoplasm: Furthermore, AXL and MER signalling induces expression of PD-L1 and PD-L2 (Programmed death-ligand 1 and 2) immune checkpoint proteins in tumour and myeloid cells inhibiting T-cell anti-tumour activity [60–62].